TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer

Hope S. Rugo, Aditya Bardia, Sara M. Tolaney, Carlos Arteaga, Javier Cortes, Joohyuk Sohn, Frederik Marmé, Quan Hong, Rosemary J. Delaney, Amir Hafeez, Fabrice André, Peter Schmid

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Patients with HR+/HER2-metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2-MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician's choice in HR+/HER2-MBC. Trial registration number: NCT03901339.

Original languageEnglish (US)
Pages (from-to)705-712
Number of pages8
JournalFuture Oncology
Volume16
Issue number12
DOIs
StatePublished - Apr 2020

Keywords

  • HER2-negative
  • HR-positive
  • MBC
  • SN-38
  • Trop-2
  • antibody-drug conjugate
  • metastatic breast cancer
  • sacituzumab govitecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Rugo, H. S., Bardia, A., Tolaney, S. M., Arteaga, C., Cortes, J., Sohn, J., Marmé, F., Hong, Q., Delaney, R. J., Hafeez, A., André, F., & Schmid, P. (2020). TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. Future Oncology, 16(12), 705-712. https://doi.org/10.2217/fon-2020-0163